期刊文献+

晚期非小细胞肺癌组织中ERCC1、RRM1和BRCA1的表达研究 被引量:7

Expression of ERCC1,RRM1 and BRCA1 in tissues of advanced non-small cell lung cancer
下载PDF
导出
摘要 目的探讨晚期非小细胞肺癌(NSCLC)组织中DNA修复基因家族成员ERCC1、RRM1和BRCA1的表达及其临床意义。方法应用免疫组织化学方法对122例晚期NSCLC组织进行ERCC1、RRM1及BRCA1蛋白表达检测。回顾性分析NSCLC患者的临床特征、化疗反应及预后与肿瘤组织中ERCC1、RRM1和BRCA1蛋白表达的关系。结果 122例晚期NSCLC组织中ERCC1、RRM1和BRCA1蛋白表达阳性率分别为47.5%、35.2%和46.7%。ERCC1和RRM1蛋白表达阳性率与患者的性别、年龄、吸烟状况、体力状况ECOG评分及肿瘤临床分期和组织学类型均无明显相关性(P>0.05);女性患者肿瘤组织BRCA1蛋白表达阳性率(63.6%)显著高于男性患者(40.4%)。ERCC1和BRCA1蛋白表达阳性与阴性患者的化疗有效率、中位生存期和1年生存率比较差异均无统计学意义(P>0.05);RRM1蛋白表达阳性患者的化疗有效率和1年生存率均显著低于RRM1蛋白表达阴性患者(P<0.05)。结论肿瘤组织中RRM1蛋白表达与晚期NSCLC患者的化疗疗效及预后密切相关。 Objective To investigate the expression of DNA repair gene family members of ERCC1,RRM1 and BRCA1 in tissues of advanced non-small cell lung cancer(NSCLC),and explore its clinical significance. Methods The expression of ERCC1,RRM1 and BRCA1 protein in 122 cases of advanced NSCLC was detected by immunohistochemical methods.The relationship between the expression of ERCC1,RRM1 and BRCA1 protein and the clinical characteristics,response to chemotherapy and prognosis were explored. Results The positive expression of ERCC1,RRM1 and BRCA1 protein in 122 cases was 47.5%,35.2% and 46.7%,respectively.There was no significant correlation between the positive expression of ERCC1 and RRM1 protein and gender,age,smoking status,ECOG physical status scale score,clinical stages and histological types(P>0.05),and the expression of BRCA1 protein in females(63.6%) was significantly higher than that in males(40.4%).There was no significant difference in response rates to chemotherapy,median survival time and 1-year survival rate between patients with positive expression of ERCC1 and BRCA1 protein and those with negative expression of ERCC1 and BRCA1 protein(P>0.05).Patients with positive expression of RRM1 protein had significantly lower response rates to chemotherapy and 1-year survival rate than those with negative expression of RRM1 protein(P<0.05). Conclusion The expression of RRM1 protein in cancer tissues is closely related to the response to chemotherapy and prognosis in patients with advanced NSCLC.
出处 《上海交通大学学报(医学版)》 CAS CSCD 北大核心 2011年第3期290-294,共5页 Journal of Shanghai Jiao tong University:Medical Science
基金 上海市科委科技发展基金(06DZ19501) 上海市科委学科带头人计划项目(09XD1403500)~~
关键词 DNA修复基因家族 ERCC1 RRM1 BRCA1 预后 非小细胞肺癌 DNA repair gene family ERCC1 RRM1 BRCA1 prognosis non-small cell lung cancer
  • 相关文献

参考文献11

  • 1Rosell R,Cobo M,Isla D,et al.Pharmacogenomics and gemcit-abine. Annals of Oncology . 2006
  • 2Soria J,Haddad V,Olaussen KA,et al.Immunohistochemical stai-ning of the Excision Repair Cross-Complementing 1 (ERCC1)pro-tein as predictor for benefit of adjuvant chemotherapy (CT)in theInternational Lung Cancer Trial (IALT). Journal of Clinical Oncology . 2006
  • 3Rosell R,Scagliotti G,Danenberg KD,et al.Transcripts in pre-treatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer. Oncegene . 2003
  • 4de Laat WL,Jaspers NG,Hoeijmakers JH.Molecular mechanism of nucleotide excision repair. Genes and Development . 1999
  • 5Rinaldi M,Cauchi C,Gridelli C.First line chemotherapy in advanced or metastatic NSCLC. Annals of Oncology . 2006
  • 6P Sève,C Dumontet.Chemoresistance in non-small cell lung cancer. Curr Med Chem Anticancer Agents . 2005
  • 7Arora,A,Siddiqui,IA,Shukla,Y.Modulation of p53 in 7,12-dimethylbenz[a]anthracene-induced skin tumors by diallyl sulfide in Swiss albino mice. Molecular Cancer Therapeutics . 2004
  • 8Rosell R,,Cecere F,Santarpia M, et al.Predicting the outcome of chemotherapy for lung cancer. Current Opinion in Pharmacology . 2006
  • 9Taron M,Rosell R,Felip E,et al.BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Human Molecular Genetics . 2004
  • 10Ceppi P,Volante M,Novello S,et al.ERCC1and RRM1gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Annals of Oncology . 2006

同被引文献70

  • 1单莉,刘甚红,韩志刚.BRCA1在晚期非小细胞肺癌组织中的表达及预后意义[J].新疆医科大学学报,2008,31(12):1724-1726. 被引量:1
  • 2徐燕,陆友金,王道兵,孟刚.肺癌组织中胸苷酸合酶与细胞增生核抗原蛋白的表达[J].安徽医科大学学报,2007,42(1):12-16. 被引量:2
  • 3陈芹,周彩存,张颉.ERCC1、RRM1和BRCA1在非小细胞肺癌中的表达及预后意义[J].肿瘤,2007,27(9):719-722. 被引量:57
  • 4Siddik ZH. Cisplatin:mode of cytotoxic action and molecular basis of resistance [ J ]. Oncogene ,2003,22 (47) :7265-7279.
  • 5Fujii T, Toyooka S, Ichimura K, et al. ERCC1 protein expression predicts the response of cisplatin-based neoadjuvant chemotherapy in non-small-cell lung cancer [ J J. Lung Cancer, 2008,59 ( 3 ) : 377-384.
  • 6Ota S, Ishii G, Goto K. Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non- small-cell lung cancer treated with eisplatin-based chemotherapy [ J]. Lung Cancer,2009,64( 1 ) :98-104.
  • 7Azuma K, Sasada T, Kawahara A, et al. Expression of ERCC1 and class III beta-tubulin in non-small cell lung caneer patients treated with carboplatin and paelitaxel [ J ]. Lung Cancer,2009,64 (3) :326-333.
  • 8Ceppi P, Volante M, Saviozzi S, et al. Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase [ J ]. Cancer, 2006,107 (7) : 1589-1596.
  • 9韩宝惠.肺癌治疗中若干热点问题的探讨[J].临床肿瘤学杂志,2007,12(10):721-727. 被引量:11
  • 10Jazieh AR, Bamefleh H, Demirkazik A, et al. Modification and implementation of NCCN guidelines on non-small cell lung cancer in the Middle East and North Africa region [ J]. J Natl Compr Canc Netw, 2010,8 ( Suppl 3 ) : S16 - 21.

引证文献7

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部